Want to see SE:SUS full AI Analyst Report?
SUS Stock Chart & Stats
kr84.50
-kr3.20(-2.25%)
At close: 4:00 PM EST
kr84.50
-kr3.20(-2.25%)
Day’s Range― - ―
52-Week Rangekr23.70 - kr162.60
Previous CloseN/A
Volume39.18K
Average Volume (3M)1.61M
Market Cap
kr1.57B
Enterprise Valuekr884.60
Total Cash (Recent Filing)kr667.73M
Total Debt (Recent Filing)kr2.15M
Price to Earnings (P/E)29.9
Beta0.65
Next Earnings
Aug 19, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.03
Shares Outstanding51,026,237
10 Day Avg. Volume583,608
30 Day Avg. Volume1,614,194
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)kr1.00B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthAn exceptionally conservative balance sheet with near-zero leverage and ~SEK 668m net cash materially reduces solvency risk and gives management durable optionality. Over 2–6 months this supports continued R&D, targeted M&A or capex (Tel Aviv facility) and cushions FX or license-revenue shocks without refinancing stress.
Cash GenerationPositive operating and free cash flow with a recent rebound demonstrates the company can self-fund growth initiatives and working-capital needs. Durable cash generation underpins reinvestment in product development, production scaling and customer support, reducing dependence on external capital over the medium term.
Product & Robotics PipelineDiversifying robotics license relationships and accelerating product launches (ultrasound, shared platform modules) strengthen competitive positioning. A broader customer base and modular content increase switching costs and recurring-license potential, making revenue more sustainable once new license contracts scale.
Bears Say
Intuitive License ReversionA known, multi-quarter reduction in Intuitive-related license revenue is a structural headwind to recurring revenues and shortens near-term margin headroom. Replacing SEK 60–90m requires new customer wins or higher volumes, increasing execution risk and making short-term growth and margin targets harder to meet.
Margin CompressionMaterial compression in operating and net margins versus prior years signals weaker operating leverage and higher cost or FX pressure. Sustained margin recovery depends on successful price realization, unit-cost reductions (production scaling) and FX normalization, all of which require multi-quarter execution to restore prior profitability levels.
Regional & Sales Lumpy RiskStructural local competition in China and notable near-term declines in Americas/APAC reflect geographic concentration and lumpy project timing. Over the medium term this raises revenue volatility, pressures customer acquisition strategy and may force increased local investment or pricing concessions to maintain market share.
Surgical Science Sweden AB News
SUS FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was kr23.70 and its highest was kr162.60 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is kr1.57B.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 24 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported kr0.37 earnings per share for the quarter, beating the consensus estimate of kr0.305 by kr0.065.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.4.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of kr0.37 in its last earnings report, beating expectations of kr0.305. Following the earnings report the stock price went up 12.785%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SE:SUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
Technical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Saniona AB
―
C-Rad AB Class B
―